Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: IXICO plc

Market Cap 18.86M 25.16M 21.84M 20.13M 35.24M 2.41B 35.97M 240M 92.97M 1.16B 94.47M 92.43M 4.04B P/E Ratio 2026 *
-5.41x
P/E Ratio 2027 * -6.65x
Enterprise Value 9.26M 12.36M 10.72M 9.88M 17.3M 1.18B 17.66M 118M 45.65M 570M 46.38M 45.38M 1.98B EV / Sales 2026 *
1.23x
EV / Sales 2027 * 1.46x
Free-Float
89.2%
Yield 2026 *
-
Yield 2027 * -
3 years 0.07
Extreme 0.07
0.3
5 years 0
Extreme 0.003
1.09
10 years 0
Extreme 0.003
1.47
Manager TitleAgeSince
Chief Executive Officer 53 19/08/2024
Director of Finance/CFO 50 21/08/2019
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Chairman 51 -
Director/Board Member 50 21/08/2019
Director/Board Member 60 21/01/2022
Change 5-day change 1-year change 3-year change Capi.($)
-53.33%-.--% - - 25.16M
-1.03%+0.60%-16.27%-13.05% 42.96B
+3.07%+3.53%+275.82%+510.43% 31.73B
-1.06%-2.04%+12.93%-15.20% 30.22B
+1.88%-1.55%-3.84%+24.72% 28.94B
-0.66%-5.84%+7.59%+12.76% 23.87B
-0.47%+4.35%+55.92%+117.41% 13.57B
-0.19%-1.11%+6.26%+7.79% 12.96B
+3.15%+5.89% - - 13.39B
-0.63%-0.87%+107.27%+77.35% 12.2B
Average -4.93%-1.99%+55.71%+90.28% 23.31B
Weighted average by Cap. +0.41%-2.40%+54.27%+95.87%

Financials

2026 *2027 *
Net sales 7.5M 10.01M 8.68M 8M 14.01M 958M 14.3M 95.48M 36.97M 462M 37.56M 36.75M 1.61B 9M 12.01M 10.42M 9.61M 16.82M 1.15B 17.17M 115M 44.36M 554M 45.08M 44.1M 1.93B
Net income -2.4M -3.2M -2.78M -2.56M -4.48M -307M -4.58M -30.55M -11.83M -148M -12.02M -11.76M -514M -2.8M -3.74M -3.24M -2.99M -5.23M -358M -5.34M -35.65M -13.8M -172M -14.02M -13.72M -600M
Net Debt -9.6M -12.81M -11.11M -10.25M -17.94M -1.23B -18.31M -122M -47.32M -591M -48.08M -47.05M -2.06B -5.7M -7.6M -6.6M -6.08M -10.65M -728M -10.87M -72.57M -28.1M -351M -28.55M -27.93M -1.22B
Logo IXICO plc
IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Employees
79
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0865GBP
Average target price
0.2600GBP
Spread / Average Target
+200.58%

Annual profits - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!